Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 347

Results For "ED"

9539 News Found

Senores Pharma forms new subsidiary in US
News | November 06, 2025

Senores Pharma forms new subsidiary in US

Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals


Novo Nordisk presents four new analyses on oral semaglutide 25 mg at ObesityWeek 2025
Clinical Trials | November 06, 2025

Novo Nordisk presents four new analyses on oral semaglutide 25 mg at ObesityWeek 2025

Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively


Zydus wellness reports 31% growth in net sales in Q2 FY26
News | November 06, 2025

Zydus wellness reports 31% growth in net sales in Q2 FY26

During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries


Cupid bags largest share in South Africa’s 5-year National Condom Program
News | November 06, 2025

Cupid bags largest share in South Africa’s 5-year National Condom Program

Cupid has been allocated approximately 23.4 million units of female condoms per year


Marksans Pharma’s UK Arm Relonchem secures MHRA nod for Exemestane 25mg Tablets
News | November 06, 2025

Marksans Pharma’s UK Arm Relonchem secures MHRA nod for Exemestane 25mg Tablets

Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women


Sumitomo Pharma America unveils promising new leukemia and myelofibrosis data ahead of ASH 2025
Clinical Trials | November 06, 2025

Sumitomo Pharma America unveils promising new leukemia and myelofibrosis data ahead of ASH 2025

Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis


Teva reports 11th consecutive quarter of growth
News | November 06, 2025

Teva reports 11th consecutive quarter of growth

Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.


Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia
Drug Approval | November 06, 2025

Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia

Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval


EazeBio and UC Santa Cruz partner to advance instrument-free diagnostic platform
News | November 06, 2025

EazeBio and UC Santa Cruz partner to advance instrument-free diagnostic platform

Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible


Ginkgo Bioworks and Bayer renew partnership to power the next wave of Ag Biologicals
News | November 06, 2025

Ginkgo Bioworks and Bayer renew partnership to power the next wave of Ag Biologicals

Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform